Skip to main content


Guideline Updates

NCCN Updates Clinical Practice Guidelines for CLL/SLL

December 14, 2020

The National Comprehensive Cancer Network (NCCN) recently released an updated version of its clinical practice guideline for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

For patients without del(17p)/TP53 mutations:

  • Relapsed/Refractory Therapy was changed to Second-Line and Subsequent Therapy
  • Frail patients with significant comorbidity and patients aged >65 years without significant comorbidities
    • Zanubrutinib was added as a second-line and subsequent therapy option for patients with intolerance or contraindication to other BTK inhibitors as a category 2A recommendation; other recommended regimen.

For patients with del(17p)/TP53 mutation:

  • Relapsed /Refractory Therapy was changed to Second-Line and Subsequent Therapy
  • Zanubrutinib was added as a first-line therapy option for patients with contraindication to other BTK inhibitors as a category 2A recommendation; other recommended regimen.
  • Zanubrutinib was added as a second-line and subsequent therapy option for patients with intolerance or contraindication to other BTK inhibitors as a category 2A recommendation; other recommended regimen.

Zanubrutinib is an FDA-accelerated approved drug for the treatment of adult patients with mantle cell lymphoma (MCL) who have received ≥1 prior therapy. Zanubrutinib is also listed in the NCCN Guidelines as a Category 2A for second line therapy in MCL.  However, zanubrutinib is not FDA-approved for any other indications at this time, including CLL/SLL.

The NCCN Drugs and Biologics CompendiumTM to the Centers for Medicare & Medicaid services states that “indications that the NCCN Drugs and Biologics CompendiumTM lists as “recommended” will be considered medically accepted indications for the purposes of determining coverage policy.”Janelle Bradley

Back to Top